<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00776191</url>
  </required_header>
  <id_info>
    <org_study_id>2005-005434-12</org_study_id>
    <nct_id>NCT00776191</nct_id>
  </id_info>
  <brief_title>Randomized Multicenter Cross-over Study to Compare the Effect of Physioneal 35 to 40 on the Protein Metabolism</brief_title>
  <acronym>NephropaedPD01</acronym>
  <official_title>Randomized, Multicenter Cross-over Study in Investigating the Effect of Bicarbonate-based Solutions (Physioneal 35 vs. 40) on Protein Metabolism in Children and Adolescents on Chronic Peritoneal Dialysis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Erlangen-Nürnberg Medical School</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Erlangen-Nürnberg Medical School</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to demonstrate an increase in protein metabolism during&#xD;
      treatment with Physioneal 35® (containing lactate 10 mmol/l, calcium 1.75 mmol/l) compared to&#xD;
      treatment with Physioneal 40® (containing lactate 15 mmol/l, calcium 1.25 mmol/l) in children&#xD;
      and adolescents with end stage renal failure receiving peritoneal dialysis.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      -  Fat oxidation (13C-enrichment in expiration breath samples for U-C13-algae turnover)&#xD;
&#xD;
        -  Growth markers (plasma levels of IgF-1, IgF-BP3, leptin)&#xD;
&#xD;
        -  Biochemical markers of anabolism (plasma levels of total protein, albumin, transferrin)&#xD;
&#xD;
        -  Serum thyroid function (fT3, fT4, TSH)&#xD;
&#xD;
        -  Serum lipid status&#xD;
&#xD;
        -  Serum markers of calcium/phosphate metabolism (PTH, calcium, ionized calcium, phosphate,&#xD;
           alkaline phosphatase)&#xD;
&#xD;
        -  Prevalence of metabolic acidosis/ alkalosis (venous sample), serum lactate&#xD;
&#xD;
        -  Safety parameters (such as normalized weekly Kt/v, parameters of glucose metabolism,&#xD;
           parameters of hepatic function, parameters of calcium-phosphate-metabolism, physical&#xD;
           examination incl. standing height, weight, assessment of complications related to&#xD;
           peritoneal dialysis as peritonitis, exit infections and inguinal hernia)&#xD;
&#xD;
        -  Body composition (lean body mass and body fat mass/fluid)&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    al study sites stoped on 15/05/2012 because of insufficient recrutement.&#xD;
  </why_stopped>
  <start_date>September 2008</start_date>
  <completion_date type="Actual">May 2012</completion_date>
  <primary_completion_date type="Actual">May 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To demonstrate an increase in protein metabolism during treatment with Physioneal 35® compared to treatment with Physioneal 40® in children and adolescents with end stage renal failure receiving peritoneal dialysis.</measure>
    <time_frame>16 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To demonstrate a improved Fat oxidation during treatment with Physioneal compared to treatment with Physioneal 40® in children and adolescents with end stage renal failure receiving peritoneal dialysis.</measure>
    <time_frame>16 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">5</enrollment>
  <condition>Endstage Renal Disease</condition>
  <arm_group>
    <arm_group_label>Physioneal 35 vs. 40</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Physioneal 35® Glucose solution with Bicarbonate 25 mmol/l, Lactate 10 mmol/l, and Calcium 1.75 mmol/l for eight weeks, followed by Physioneal 40® Glucose solution Bicarbonate 25 mmol/l, Lactate 15 mmol/l, and Calcium 1.25 mmol/l for eight weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Physioneal 40 vs. 35</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Physioneal 40® Glucose solution Bicarbonate 25 mmol/l, Lactate 15 mmol/l, and Calcium 1.25 mmol/l for eight weeks followed by Physioneal 35® Glucose solution with Bicarbonate 25 mmol/l, Lactate 10 mmol/l, and Calcium 1.75 mmol/l for eight weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Physioneal 35</intervention_name>
    <description>Physioneal 35® for eight weeks, followed by Physioneal 40® for eight weeks</description>
    <arm_group_label>Physioneal 35 vs. 40</arm_group_label>
    <other_name>Nephropaed-PD-01/B</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Physioneal 40</intervention_name>
    <description>Physioneal 40® for eight weeks followed by Physioneal 35® for eight weeks</description>
    <arm_group_label>Physioneal 40 vs. 35</arm_group_label>
    <other_name>Nephropaed-PD-01/B</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients who are males or non-pregnant females between the ages of 3 months and 18&#xD;
             years.&#xD;
&#xD;
          -  Patients who are on regular automated peritoneal dialysis due to end stage renal&#xD;
             failure for at least 3 months.&#xD;
&#xD;
          -  Patients and/or their parents must be capable of understanding the purpose and risks&#xD;
             of the study.&#xD;
&#xD;
          -  Patients and/or their parents (or guardians) who are willing to give written informed&#xD;
             consent and willing to participate in and comply with the study protocol.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Use of pure lactate, amino acid or oligosaccharide solutions for peritoneal dialysis&#xD;
&#xD;
          -  Peritonitis episode less than 6 weeks before enrolment&#xD;
&#xD;
          -  Hypercalcemia (serum) &gt; 2.75 mmol/l in three independent measurements during 10 days&#xD;
&#xD;
          -  Severe secondary hyperthyroidism (iPTH &gt; 500 ng/l)&#xD;
&#xD;
          -  Renal anemia with hemoglobin (blood) &lt; 10 mg/dl&#xD;
&#xD;
          -  Impaired hepatic function (AST/SGOT or ALT/SGPT &gt; 2 times the upper limit of the&#xD;
             reference range)&#xD;
&#xD;
          -  Patients who are participating in another study that requires Ethics Committee&#xD;
             approval. Non-interventional studies are permitted.&#xD;
&#xD;
          -  Pregnant female patients, females of childbearing potential who are unwilling or&#xD;
             unable to use adequate contraception methods.&#xD;
&#xD;
          -  Severe respiratory insufficiency&#xD;
&#xD;
          -  Malnourishment (body weight &lt; -2.5 SDS for height and gender) or severe deterioration&#xD;
             of fat metabolism&#xD;
&#xD;
          -  Patients with a history of malignancy of any organ system, treated or untreated&#xD;
&#xD;
          -  Any surgical or medical condition which might significantly alter the absorption,&#xD;
             distribution, metabolism, or excretion of the investigational product and the&#xD;
             comparator, including&#xD;
&#xD;
               -  Major deterioration of the abdominal wall (e.g. dermal infections or burns,&#xD;
                  hernia)&#xD;
&#xD;
               -  Major deterioration of the abdominal cavity (e.g. ascites, ileus, adhesions,&#xD;
                  bowel perforation, defects of the diaphragm, tumours)&#xD;
&#xD;
          -  Patients with a history of viral infections such as HIV or hepatitis B, C.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Months</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joerg Doetsch, Prof. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital Erlangen, Department of Pediatrics University Hospital Koeln</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pediatric Nephrology, Universiy Children's Hospital</name>
      <address>
        <city>Cologne</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dept. of Pediatric Nephrology, University Hospital Erlangen</name>
      <address>
        <city>Erlangen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dept. of Pediatric Nephrology, University of Hannover</name>
      <address>
        <city>Hannover</city>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dept. of Nephrology, children´s hospital Memmingen</name>
      <address>
        <city>Memmingen</city>
        <zip>87700</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dept. of Nephrology, University of Rostock</name>
      <address>
        <city>Rostock</city>
        <zip>18057</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>June 2015</verification_date>
  <study_first_submitted>October 20, 2008</study_first_submitted>
  <study_first_submitted_qc>October 20, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 21, 2008</study_first_posted>
  <last_update_submitted>June 3, 2015</last_update_submitted>
  <last_update_submitted_qc>June 3, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 4, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Physioneal 35</keyword>
  <keyword>Physioneal 40</keyword>
  <keyword>children</keyword>
  <keyword>chronic peritoneal dialysis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Failure, Chronic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

